

SynAct Pharma introduces resomelagon as generic name for AP1189

SynAct Pharma AB (publ) ("SynAct") today announced it will introduce the generic name resomelagon for its lead candidate AP1189, a biased melanocortin receptor agonist developed for treatment of active inflammatory and autoimmune diseases. Resomelagon was recently included by the World Health Organization (WHO) on list 89 of recommended International Nonproprietary Names (INN), to denote the structure of the active part of AP1189.

"We are pleased that WHO has assigned a generic name for our leading drug candidate, AP1189, targeting inflammatory and autoimmune diseases such as rheumatoid arthritis," said Jeppe Øvlesen, CEO of SynAct Pharma. "The company is working hard to advance its development programs in RA. We are on track and still expect data from both our clinical phase 2 studies, RESOLVE and EXPAND, in the second half of 2023, and we will introduce the new name, resomelagon (AP1189), in our future communication."

The INN expert group at WHO has agreed to use the suffix "-melagon" for designation of the non-peptidic melanocortin 1 and 3 agonists. The prefix "reso", specific to AP1189, is referring to its effect on resolution of inflammation.

List 89 of recommended INN, including resomelagon, will be published in WHO Drug Information, Vol 37, No 1, 2023. According to the WHO, INNs facilitate the identification of pharmaceutical substances or active pharmaceutical ingredients. Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

The information was submitted, through the agency of the contact person below, for publication at 07:00 a.m CEST on March 30, 2023

For further information, please contact:

Jeppe Øvlesen, CEO
Phone: +45 28 44 75 67
Mail: joo@synactpharma.com

Thomas Jonassen, CSO
Phone: +45 40 15 66 69
Mail: tj@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma.com.

About resomelagon (AP1189)

The mechanism of action of SynAct Pharma's candidate drug, resomelagon (AP1189), is to promote resolution of inflammation through selective activation of melanocortin receptors 1 and 3. These receptors are located on all immune cell types including macrophages and neutrophils. Activation of these receptors results in two direct anti-inflammatory effects: it turns these cells to produce less pro-inflammatory molecules and also to switching them to perform inflammation "clean-up", known as efferocytosis (J Immun 2015, 194:3381-3388). This effect has shown to be effective in disease models of inflammatory and autoimmune diseases and the clinical potential of the approach is currently tested in clinical programs in patients with rheumatoid arthritis (RA), nephrotic syndrome (NS) and COVID-19. The safety and efficacy of resomelagon (AP1189) is being tested and has not been reviewed by any regulatory authority worldwide.

Attachments

[SynAct Pharma introduces resomelagon as generic name for AP1189](#)